KeyBanc upgraded Certara to Overweight from Sector Weight with a $23 price target. The upgrade reflects increased estimates and higher conviction of top-line trends, the analyst tells investors in a research note. The firm sees Certara achieving midpoint of its guidance range based on commentary around improving biotech end markets from bio-simulation peers.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CERT:
- Certara to Report First Quarter 2024 Financial Results on May 7th, 2024 and Participate in the BofA Securities Healthcare Conference
- Certara initiated with a Market Perform at JMP Securities
- Certara price target raised to $20 from $17 at UBS
- Certara sees FY24 EPS 41c-46c, consensus 48c
- Certara reports Q4 EPS 9c, consensus 11c
